1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Delayed London Stock Exchange  -  11:35 2022-08-12 am EDT
10712.00 GBX   +1.96%
08/12Seagen loses arbitration against Daiichi Sankyo over drug technology
RE
08/12Seagen loses arbitration ruling against Daiichi Sankyo
RE
08/12European Stocks Close Higher After UK GDP, Eurozone Industrial Production Data
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

EU Drug Regulator Approves AstraZeneca's COVID-19 Vaccine as Third-Dose Booster

05/23/2022 | 11:08pm EDT


© MT Newswires 2022
All news about ASTRAZENECA PLC
08/12Seagen loses arbitration against Daiichi Sankyo over drug technology
RE
08/12Seagen loses arbitration ruling against Daiichi Sankyo
RE
08/12European Stocks Close Higher After UK GDP, Eurozone Industrial Production Data
MT
08/12Sanofi Says First Patient Enrolled in Study to Investigate Protection Against Respirato..
MT
08/12Guardant Health Says FDA Approved Liquid Biopsy Test as Companion Diagnostic for Lung C..
MT
08/12Enhertu approved in the US as the first HER2-directed therapy for patients with previou..
AQ
08/12ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directe..
BU
08/12ASTRAZENECA : Enhertu approved in the US as the first HER2-directed therapy for patients w..
PU
08/12AstraZeneca, Daiichi Sankyo Receive FDA Approval for Lung Cancer Drug
MT
08/12AstraZeneca's Lung Cancer Drug Secures US FDA's Nod
MT
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2022 44 198 M - -
Net income 2022 4 471 M - -
Net Debt 2022 24 385 M - -
P/E ratio 2022 46,3x
Yield 2022 2,27%
Capitalization 201 B 201 B -
EV / Sales 2022 5,10x
EV / Sales 2023 4,73x
Nbr of Employees 83 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 129,86 $
Average target price 144,14 $
Spread / Average Target 11,0%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC23.44%201 219
JOHNSON & JOHNSON-3.37%434 603
ELI LILLY AND COMPANY11.53%292 730
PFIZER, INC.-15.14%281 235
ROCHE HOLDING AG-16.91%275 562
ABBVIE INC.5.32%252 131